Show simple item record

dc.contributor.authorWang, H.
dc.contributor.authorHatzixanthis, K.
dc.contributor.authorBarnard, A.
dc.contributor.authorShah, R.
dc.contributor.authorSaveri, E.
dc.contributor.authorPitts, K.
dc.contributor.authorPiwowarczyk, D.
dc.contributor.authorPatil, G.
dc.contributor.authorBaines, Simon D.
dc.contributor.authorWilkinson, A.
dc.contributor.authorFairhead, H.
dc.date.accessioned2014-11-12T10:44:27Z
dc.date.available2014-11-12T10:44:27Z
dc.date.issued2011-09
dc.identifier.citationWang , H , Hatzixanthis , K , Barnard , A , Shah , R , Saveri , E , Pitts , K , Piwowarczyk , D , Patil , G , Baines , S D , Wilkinson , A & Fairhead , H 2011 , ' SASP: targeted delivery to Gram-negative pathogens ' , 51st Interscience Conf on Antimicrobial Agents and Chemotherapy (ICAAC) , Chicago , United States , 17/09/11 - 20/09/11 .
dc.identifier.citationconference
dc.identifier.urihttp://hdl.handle.net/2299/14739
dc.description.abstractBackground: Gram-negative bacteria are responsible for significant morbidity and mortality worldwide. Multi-drug resistance emergence has rendered many therapies ineffective. New therapies are urgently required to widen treatment options. SASPject technology delivers small acid-soluble spore protein (SASP) genes to target bacteria using modified bacteriophage vectors, resulting in rapid killing. SASP is a unique antibacterial protein that non-specifically binds bacterial DNA and halts DNA replication and gene expression. In this study we present the first data for a Gram-negative targeted SASPject vector (PT3.1) which shows in vitro activity against Escherichia coli (EC) and Pseudomonas aeruginosa (PA). Methods: We evaluated efficacy of SASPject PT3.1 vs. EC (N=5) & PA (N=5) using a microtitre tray fixed duration (3 h) kill method. Log-phase cultures (1x105 cfu/mL) were prepared in supplemented (MgSO4 & CaCl2, 5 mM; glucose, 0.1% w/v) LB broth (LBC) & exposed to 2x108 plaque forming units (pfu)/mL of PT3.1. PT3.1 antimicrobial activity was determined using agar-based culture following incubation (37oC). Additionally, rate of PT3.1 kill was determined using a kill-curve technique; a selection of EC & PA strains from the fixed duration kill study were evaluated & bacterial viable counts determined over 3 h on LBC agar. Results: SASPject PT3.1 elicited good antimicrobial activity vs. EC & PA evaluated in this study; the median reduction in viable counts for PT3.1-treated cultures in the fixed 3 h kill was 99.1%. Kill curve data suggested rapid EC & PA killing; viable counts (log10 cfu/mL range) of PT3.1-treated cultures were 2.36->4.01, 3.04-4.06, and 3.40-4.16 lower than corresponding controls after 1, 2, and 3 h respectively. Conclusions: 1. SASPject PT3.1 demonstrated good antimicrobial activity vs. EC & PA evaluated in this study in a fixed 3 h exposure period 2. PT3.1 was bactericidal (≥3 log10 cfu/mL decline) vs. 3 of 4 isolates (1EC & 2PA) evaluated in time-kill curves after 1 h and against all isolates after 2 h 3. Further evaluations of Gram-negative SASPject phage are warranteden
dc.language.isoeng
dc.titleSASP: targeted delivery to Gram-negative pathogensen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionMicrobiology and Biotechnology
dc.contributor.institutionBiosciences Research Group
dc.contributor.institutionCentre for Research in Mechanisms of Disease and Drug Discovery
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Future Societies Research
dc.description.statusNon peer reviewed
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record